Dermatitis News

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate to severe atopic dermatitis that topical therapies have not adequately controlled, according to a press release.

Self-guided cognitive behavioral therapy was non-inferior in reducing atopic dermatitis symptom severity as clinician-guided cognitive behavioral therapy, according to a study.

MIAMI BEACH, Fla. — The production of isocyanate compounds from the environment may explain the increasing prevalence of atopic dermatitis, according to a speaker at Masters of Pediatric Dermatology.

MIAMI BEACH, Fla. — Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.

MIAMI BEACH, Fla. — Topical steroid withdrawal syndrome may signal a reminder to clinicians to be good stewards of topical treatments, according to a speaker at Masters of Pediatric Dermatology.

The phase 3 DELTA TEEN trial evaluating Anzupgo 20 mg/g cream for the treatment of chronic hand eczema in adolescents has shown positive results, LEO Pharma announced in a press release.

Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of tralokinumab for the treatment of atopic dermatitis.

Long-term treatment with lebrikizumab may be beneficial for patients with atopic dermatitis that were not initially responders to the treatment, according to a study.